Post Holdings is still considered a 'Strong Buy' even after its share price fell nearly 30% and net debt increased. The company reported revenue growth to $6.17 billion for the first nine months of 2026, with strong performance in its Post Consumer Brands and Weetabix segments. Management is focusing on aggressive share buybacks rather than reducing debt, aiming to capitalize on the stock's undervaluation and boost shareholder value. Post Holdings trades at a discount compared to peers on valuation metrics like EV/EBITDA, with EBITDA expected to rise to $1.565 billion this year, signaling potential for future gains.
Post Holdings is the subject of this news, with Pluang's Consumer Staples sector data providing market context as of Nov 07, 2026 03:31 WIB. Among 63 priced US Consumer Staples stocks on Pluang, 13 rose and 48 fell today. Notable movers include XXII (22nd Century Group Inc) down 15.14% with 90% sell orders, DNUT (Krispy Kreme Inc) down 7.83% with balanced buy/sell orders, and ELF (e l f Beauty Inc) up 7.56% despite 100% sell orders. The most notable figure is the 15.14% decline in XXII's price.
The music duo for KING + COUNTRY released the Drummer Boy (Original Motion Picture Soundtrack) to coincide with the nationwide launch of their Christmas film DRUMMER BOY. The soundtrack features original songs by Joel and Luke Smallbone, reimagined C...
HMG Strategy is holding its first Tennessee C-Level Technology Leadership Summit on November 13 at W Nashville, bringing together CIOs, CISOs, CTOs, and senior tech executives from across Tennessee and the Mid-South. The summit will focus on AI, cybe...
Ipsen has disclosed its monthly update on the total number of shares and voting rights as of October 31, 2026. The company reported 83,814,526 shares composing the share capital, with a gross total of 132,059,377 voting rights and a net total of 130,...
At its 2026 International User Summit, Chery unveiled its Globalization 3.0 strategy, moving beyond export-driven growth to emphasize deep localization, sustainable development, and community engagement. The company is expanding local R&D, manufactur...
Ipsen Pharma has disclosed the total number of shares and voting rights composing its capital as of October 31, 2026. The company reported 83,814,526 shares and a gross total of 132,059,377 voting rights, with a net total of 130,677,690 after excludi...
